Abstract
The COVID-19 is rapidly scattering worldwide, and the number of cases in the Eastern Mediterranean Region is rising. Thus, there is a need for immediate targeted actions. We designed a longitudinal study in a hot outbreak zone to analyze the serial findings between infected patients for detecting temporal changes from February 2020. In a hospital-based open-cohort study, patients are followed from admission until one year from their discharge (the 1st, 4th, 12th weeks, and the first year). The patient recruitment phase finished at the end of August 2020, and the follow-up continues by the end of August 2021. The measurements included demographic, socio-economics, symptoms, health service diagnosis and treatment, contact history, and psychological variables. The signs improvement, death, length of stay in hospital were considered primary, and impaired pulmonary function and psychotic disorders were considered main secondary outcomes. Moreover, clinical symptoms and respiratory functions are being determined in such follow-ups. Among the first 600 COVID-19 cases, 490 patients with complete information (39% female; the average age of 57±15 years) were analyzed. Seven percent of these patients died. The three main leading causes of admission were: fever (77%), dry cough (73%), and fatigue (69%). The most prevalent comorbidities between COVID-19 patients were hypertension (35%), diabetes (28%), and ischemic heart disease (14%). The percentage of primary composite endpoints (PCEP), defined as death, the use of mechanical ventilation, or admission to an intensive care unit was 18%. The Cox proportional-hazards model for PCEP indicated the following significant risk factors: Oxygen saturation < 80% (HR= 6.3; [CI 95%: 2.5,15.5]), lymphopenia (HR= 3.5; [CI 95%: 2.2,5.5]), Oxygen saturation 80%-90% (HR= 2.5; [CI 95%: 1.1,5.8]), and thrombocytopenia (HR= 1.6; [CI 95%: 1.1,2.5]). This long-term prospective Cohort may support healthcare professionals in the management of resources following this pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research leading to these results has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 712949 (TECNIOspring PLUS), and from the Agency for Business Competitiveness of the Government of Catalonia (TECSPR18-1-0017) (Marjan Mansourian), and the Spanish Ministry of Economy and Competitiveness –; Spain (DPI2017-83989-R) (Miquel Angel Mañ;anas), and Isfahan University of Medical Sciences (IR.MUI.MED.REC.1399.029) (Ramin Sami) and University of Isfahan (302419) (H.R. Marateb).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Isfahan University of Medical Sciences (IUMS) and the other national authorities approved the study (IR.MUI.MED.REC.1399.029). The experimental protocol was also conformed to the Declaration of Helsinki. Also, the entire subjects gave written informed consent to the experimental procedure. The written informed consent was given by the first relative family of patients with severe conditions. No minors participated in our study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
1. Hazard ratios and 95% confidence intervals for PECP associated with different baseline factors were estimated using Cox proportional-hazards regression models. 2. The clinical symptoms of the COVID-19 patients after the first- and fourth- week F/U were added. 3. The characteristics of 76 patients with pneumonia with a negative PCR test and CT-scan were also provided.
Data Availability
Representative samples of the COVID-19 patients were provided at https://figshare.com/s/ef91187fb69a051b8396 (50 subjects with negative PCEP and 10 subjects with positive PCEP).
